• Explore /
  • Poster
  • / A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer).

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer).

Abstract Poster

Authors

null

Ellis Glenn Levine

Roswell Park Cancer Institute, Buffalo, NY

Ellis Glenn Levine , Andres Forero , Tracy O'Connor , Ben K. Seon , Manoj A Jivani , Bonne J. Adams , Charles P. Theuer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01326481

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3057)

DOI

10.1200/jco.2013.31.15_suppl.3057

Abstract #

3057

Poster Bd #

15H

Abstract Disclosures

Similar Posters

First Author: Jason D. Lickliter

First Author: Steven Attia

First Author: Toni K. Choueiri

First Author: Lee S. Rosen